• Lytix Biopharma received a NOK 12 million grant from the Research Council of Norway.
• The funding will support new formulations of oncolytic molecules for intratumoral injections targeting deep-seated tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via Cision (Ref. ID: 202611050105BITN____UKPR__EN_20261104-BIT-5014-0) on November 05, 2026, and is solely responsible for the information contained therein.